Zhao Qing, Cui Songping, Hu Bin, Chen Shuo
Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Front Genet. 2025 Mar 18;16:1549602. doi: 10.3389/fgene.2025.1549602. eCollection 2025.
Inflammatory biomarkers have shown prognostic value in Non-Small Cell Lung Cancer (NSCLC), but the inclusion of Adenocarcinoma (AIS) cases in previous studies may introduce bias. This study aims to evaluate the prognostic significance of inflammatory biomarkers in NSCLC while excluding AIS.
This study included patients who received surgery for lung carcinoma from August 2016 and August 2019. We collected demographic, clinical, laboratory, and outcome information. Inflammatory biomarkers were analyzed using receiver operating characteristic (ROC) curves, Kaplan-Meier survival analysis, and Cox regression to assess their prognostic value.
Higher levels of inflammatory biomarkers correlated with poorer survival, with significant differences in overall survival (OS) between high- and low-expression groups. However, multivariate Cox regression identified age, tumor stage, and differentiation as independent prognostic factors, while biomarkers were not independently predictive.
Inflammatory biomarkers have short-term prognostic value in invasive NSCLC, but traditional clinical and pathological factors remain key for long-term outcomes.
炎症生物标志物已在非小细胞肺癌（NSCLC）中显示出预后价值，但先前研究纳入原位腺癌（AIS）病例可能会引入偏差。本研究旨在评估排除AIS后炎症生物标志物在NSCLC中的预后意义。
本研究纳入了2016年8月至2019年8月期间接受肺癌手术的患者。我们收集了人口统计学、临床、实验室和结局信息。使用受试者工作特征（ROC）曲线、Kaplan-Meier生存分析和Cox回归分析炎症生物标志物，以评估其预后价值。
较高水平的炎症生物标志物与较差的生存率相关，高表达组和低表达组之间的总生存期（OS）存在显著差异。然而，多变量Cox回归确定年龄、肿瘤分期和分化为独立的预后因素，而生物标志物并非独立预测因素。
炎症生物标志物在浸润性NSCLC中具有短期预后价值，但传统的临床和病理因素仍是长期预后的关键。
